Cost-Effective Hemorrhage Prevention in Ultrasound-Guided Liver Biopsy
Improving Liver Biopsy Safety with Coaxial Needles and AGS-SFA
Table of Contents
- Improving Liver Biopsy Safety with Coaxial Needles and AGS-SFA
- Liver Biopsy Safety: Q&A on Coaxial Needles and AGS-SFA
- What is a liver biopsy and why is it performed?
- What are the main risks associated with traditional liver biopsies?
- How does the coaxial needle technique improve the safety of liver biopsies?
- What is AGS-SFA and how does it help prevent bleeding after a liver biopsy?
- How is AGS-SFA administered during a liver biopsy using the coaxial technique?
A novel approach to liver biopsy considerably reduces bleeding risk and improves patient outcomes.
The Challenge of Liver Biopsy
Diagnosing and treating liver disease and focal liver lesions presents a complex challenge. A precise diagnosis is crucial for effective treatment and accurate prognosis. Liver biopsy, a surgical procedure involving the extraction of liver tissue for examination, plays a vital role in this process.
Despite advancements in medical techniques, liver biopsies carry inherent risks. Bleeding after a liver biopsy has been reported in a significant number of cases. Therefore, methods to minimize bleeding during and after the procedure are highly beneficial for both clinicians and patients.
Coaxial Technique and Bleeding Reduction
Traditional liver biopsy techniques often involve direct needle insertion. Though, a study explored the use of a coaxial method, which, while slightly increasing operative time (by approximately 3.5 minutes), dramatically reduced the risk of bleeding.
The coaxial technique involves using a larger needle to create a channel through which a smaller biopsy needle is inserted. This approach has been shown to improve safety without compromising the quality of the tissue sample obtained. It is particularly beneficial for patients with coagulation abnormalities or diffuse liver diseases.
In the study, a 17G coaxial needle and an 18G biopsy needle were used to puncture the target area and collect two tissue samples. Instantly after the biopsy, Doppler ultrasound was used to visualize blood flow within the needle path and monitor the time required for hemostasis (the process of stopping bleeding) in real time.
The control group, which underwent direct biopsy, experienced a bleeding complication rate of 22.1%, with an average hemostasis time of 5.3 minutes. This higher rate may be attributed to the inclusion of patients with chronic hepatitis B virus infection, who often have mild coagulation abnormalities and hypoalbuminemia. The use of real-time Doppler ultrasound also likely increased the detection of minor bleeding events.
Univariate analysis identified fatty liver, prothrombin time (PT), albumin levels, and international normalized ratio (INR) as significant factors influencing biopsy-related bleeding in the control group. Interestingly, patients with fatty liver appeared to have a lower risk of bleeding, possibly due to the increased density of liver tissue compressing the needle path.
AGS-SFA: A Cost-effective Hemostatic Agent
Researchers explored the use of Absorbent Gelatin Sponge-Small Fragment Agent (AGS-SFA) to prevent bleeding after liver biopsies. Common agents used include thrombin, Absorbent Gelatin Sponge-Particle Embolic Agent (AGS-PEA), and tissue glue.
Thrombin, a coagulant, activates coagulation factors and platelet aggregation.Though, it can be expensive, and its effectiveness depends on the patient’s coagulation factors and platelet count.
Tissue glue, primarily butyl cyanoacrylate, rapidly seals blood vessels.While it achieves hemostasis quickly, it is also relatively expensive and may be less stable than other options.
AGS-PEA, a liquid formulation, absorbs water and blood at the wound site, promoting hemostasis by physically blocking blood flow. It can also be combined with hemagglutinin to create a hybrid embolus.
AGS-SFA was chosen for this study due to its economic advantages. AGS-SFA is significantly cheaper than AGS-PEA. AGS-SFA promotes hemostasis by absorbing blood,swelling to compress vessels,and providing a scaffold for platelet aggregation,accelerating clot formation.
In the study, AGS-SFA was cut into small pieces and injected into the needle channel through the coaxial needle to assess its feasibility and safety.
Study Results: Reduced Bleeding with AGS-SFA
The study revealed that the group receiving AGS-SFA after the biopsy experienced a significantly lower bleeding complication rate (1.3%) and a shorter hemostasis time (0.4 minutes) compared to the control group. This suggests that AGS-SFA is effective in promoting hemostasis.
Though, all three cases of post-biopsy bleeding in the AGS-SFA group occurred in patients with severe cirrhosis, possibly due to tissue fragility or improper AGS-SFA placement. The study acknowledged a limitation in determining the optimal amount of AGS-SFA to use. Too much AGS-SFA could obstruct the needle, while insufficient or poorly placed AGS-SFA might not effectively prevent bleeding.
The researchers recommended withdrawing the tip of the coaxial needle to a specific depth below the hepatic pericardium before filling it with AGS-SFA to ensure proper placement.
Conclusion: A Promising Approach
The study concludes that using coaxial needles to inject AGS-SFA is a safe, effective, and economical method to improve the safety of liver biopsies without adding significantly to patient care.
While the study acknowledges limitations, such as the lack of operator blinding and the single-center design, the findings suggest that this approach holds promise for reducing bleeding complications and improving patient outcomes in liver biopsies.
Liver Biopsy Safety: Q&A on Coaxial Needles and AGS-SFA
Liver biopsies are crucial for diagnosing and managing liver conditions, but they also carry inherent risks. This Q&A explores a novel approach using coaxial needles and Absorbent Gelatin sponge-Small Fragment Agent (AGS-SFA) to improve the safety and outcomes of liver biopsies.
What is a liver biopsy and why is it performed?
A liver biopsy is a medical procedure where a small sample of liver tissue is extracted and examined under a microscope. It is performed to:
Diagnose liver diseases and focal liver lesions.
Determine the extent of liver damage or inflammation.
Aid in treatment planning and prognosis.
Evaluate abnormal liver function tests.[1, 3]
What are the main risks associated with traditional liver biopsies?
The primary risk associated with liver biopsies is bleeding. Other risks include infection and pain. [1, 2] Methods to minimize bleeding are highly beneficial for both clinicians and patients.
How does the coaxial needle technique improve the safety of liver biopsies?
The coaxial technique involves inserting a larger needle to create a channel, through which a smaller biopsy needle is then inserted. This approach:
Reduces the risk of bleeding compared to direct needle insertion.
Improves safety without compromising the quality of the tissue sample.
Is especially beneficial for patients with coagulation abnormalities or diffuse liver diseases.
What is AGS-SFA and how does it help prevent bleeding after a liver biopsy?
AGS-SFA stands for absorbent Gelatin Sponge-Small fragment Agent. It is a cost-effective hemostatic agent used to prevent bleeding after liver biopsies. AGS-SFA works by:
Absorbing blood at the wound site.
Swelling to compress blood vessels.
Providing a scaffold for platelet aggregation, accelerating clot formation.
How is AGS-SFA administered during a liver biopsy using the coaxial technique?
During the coaxial technique, AGS-SFA is cut into small pieces and injected into the needle channel through the coaxial needle after the biopsy sample is obtained. Study results showed that injecting AGS-SFA significantly reduces both the bleeding complication rate